60 Degrees Pharmaceuticals, INC Form 4 insider transactions

Geoffrey Dow, President and CEO of 60 Degrees Pharmaceuticals, Inc., acquired 7,350 shares of common stock.

Geoffrey S. Dow, CEO of 60 Degrees Pharmaceuticals, purchased 9,670 shares of common stock, increasing his direct beneficial ownership.

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, purchased 12,963 shares of common stock in two transactions in December 2025.

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, acquired 7,201 shares of common stock in an open-market transaction.

60 Degrees Pharmaceuticals' COO Kristen Landon received 4,167 stock options at an exercise price of $6.85, vesting over five years.

60 Degrees Pharmaceuticals' Chief Operating Officer, Kristen Landon, acquired 4,540 shares of common stock at no cost, adjusted for a recent reverse stock split.

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, Inc., acquired additional common stock, bringing his direct and indirect beneficial ownership to 37,290 shares after a recent 1-for-5 reverse stock split.

Cheryl Xu, a Director at 60 Degrees Pharmaceuticals, Inc. (SXTP), acquired 5,000 shares of common stock on June 3, 2025, increasing her direct beneficial ownership to 15,816 shares, following a 1-for-5 reverse stock split in February 2025.

Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, was granted 525,000 stock options on January 2, 2025.

Tyrone Miller, CFO of 60 Degrees Pharmaceuticals, acquired 75,000 stock options on January 2, 2025.

Geoffrey S. Dow, CEO of 60 Degrees Pharmaceuticals, reports acquiring and disposing of common stock on January 17, 2025.

Tyrone Miller, CFO of 60 Degrees Pharmaceuticals, acquired 11,626 shares of common stock on January 17, 2025.

Director Cheryl Xu has increased her holdings in 60 Degrees Pharmaceuticals (SXTP) through a series of open market purchases of common stock.

Geoffrey S. Dow, CEO of 60 Degrees Pharmaceuticals, has acquired a significant number of shares through open market purchases, increasing his direct and indirect holdings.

Geoffrey S. Dow, CEO of 60 Degrees Pharmaceuticals, has increased his holdings in the company through a series of open market purchases of common stock.

Director Cheryl Xu recently purchased 5,000 shares of 60 Degrees Pharmaceuticals at $1.70 per share, increasing her holdings to 41,078 shares.

Cheryl Xu, a director of 60 Degrees Pharmaceuticals, settled 2,000 restricted stock units for common stock on May 16, 2024.

Director Stephen Toovey settles restricted stock units for common stock in 60 Degrees Pharmaceuticals.

CFO of 60 Degrees Pharmaceuticals, Tyrone Miller, reports acquisition of common stock through settlement of restricted stock units.

Director Paul Field reports the settlement of restricted stock units into common stock of 60 Degrees Pharmaceuticals.

Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, settled restricted stock units (RSUs) in April and May, increasing his direct and indirect holdings of common stock.

Director Charles Allen settles restricted stock units for common stock in 60 Degrees Pharmaceuticals.

Knight Therapeutics and its subsidiary Knight Therapeutics International S.A. jointly file a Form 4, indicating they are no longer beneficial owners of more than 10% of 60 Degrees Pharmaceuticals' securities.